Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women

作者: Ralph P. Insinga , Gonzalo Perez , Cosette M. Wheeler , Laura A. Koutsky , Suzanne M. Garland

DOI: 10.1158/1055-9965.EPI-09-1235

关键词: MedicineSurgeryHPV infectionYoung adultIncidence (epidemiology)CervixEpidemiologyRisk of infectionInternal medicineViral diseaseContext (language use)

摘要: Background: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with risk reappearance following a period nondetection. Methods: Women (1,788) ages 16 to 23 years underwent cytologic testing PCR-based swab samples for HPV DNA (HPV-16/18/31/33/35/45/52/58/59) at ∼6-month intervals up 4 in context phase 3 clinical trial (placebo arm). type–specific rates were estimated per 100 person-years. Duration type-specific nondetection using Kaplan-Meier methods. Results: HPV-16 exhibited highest (5.9), HPV-35 HPV-33 lowest (1.0) Mean durations ranged from 13 months HPV-59 20 58 (with ongoing infections censored time treatment, if done). The within ∼3 0% 16% across types, mean 8%. Limited evidence was found role false-positive tests, missed that above threshold detection, or new acquisition accounting patterns reappearance. Conclusions: Incidence high-risk observed vary considerably more types than duration. A nontrivial proportion women nondetection, potential explanation many such events this analysis being return detectable levels previously acquired infection. Impact: has not been reported individual study finds infected exhibit reappearances. Future studies could ascertain subject-level factors potentially modify reappearance. Cancer Epidemiol Biomarkers Prev; 19(6); 1585–94. ©2010 AACR.

参考文章(32)
Paul Allison, Survival analysis using sas®: a practical guide SAS institute. ,(1995)
Jeremy Holmes, Lindsay Hemmett, Susan Garfield, The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. European Journal of Health Economics. ,vol. 6, pp. 30- 37 ,(2005) , 10.1007/S10198-004-0254-1
Anna R. Giuliano, Guillermo Tortolero-Luna, Elena Ferrer, Ann N. Burchell, Silvia de Sanjose, Susanne Kruger Kjaer, Nubia Muñoz, Mark Schiffman, F. Xavier Bosch, Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions Vaccine. ,vol. 26, ,(2008) , 10.1016/J.VACCINE.2008.06.021
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Constance Mao, Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Dorothy J. Wiley, Frances B. Alvarez, Oliver M. Bautista, Kathrin U. Jansen, Eliav Barr, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstetrics & Gynecology. ,vol. 107, pp. 18- 27 ,(2006) , 10.1097/01.AOG.0000192397.41191.FB
D. Y. Lin, L. J. Wei, The Robust Inference for the Cox Proportional Hazards Model Journal of the American Statistical Association. ,vol. 84, pp. 1074- 1078 ,(1989) , 10.1080/01621459.1989.10478874
Hugo De Vuyst, Gary M. Clifford, Maria Claudia Nascimento, Margaret M. Madeleine, Silvia Franceschi, Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International Journal of Cancer. ,vol. 124, pp. 1626- 1636 ,(2009) , 10.1002/IJC.24116
Xavier Castellsagué, Natural history and epidemiology of HPV infection and cervical cancer Gynecologic Oncology. ,vol. 110, ,(2008) , 10.1016/J.YGYNO.2008.07.045
Dorothy Wiley, Emmanuel Masongsong, Human papillomavirus: the burden of infection. Obstetrical & Gynecological Survey. ,vol. 61, ,(2006) , 10.1097/01.OGX.0000221010.82943.8C
Jane J Kim, Marc Brisson, W John Edmunds, Sue J Goldie, None, Modeling Cervical Cancer Prevention in Developed Countries Vaccine. ,vol. 26, ,(2008) , 10.1016/J.VACCINE.2008.06.009